Introduction
============

In late 2019, several people in Wuhan, China, were presenting with severe pneumonia at the hospitals. As the number of patients rapidly increased, the Chinese government decided on 23 January 2020 to lock down the city to contain the virus. Unfortunately, the virus had already spread across China and throughout the world. The World Health Organization (WHO) officially declared the outbreak a pandemic on March 11, 2020. As of 23 May 2020, over 5 million cases worldwide had been reported to WHO and the death toll has exceeded 330 000.[@R1]

Researchers isolated the virus causing the pneumonia in December 2019 and found it to be a strain of *β*-coronavirus (CoV). The virus showed a high nucleotide sequence homology with two severe acute respiratory syndrome (SARS)-like bat coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21 (88% homology) and with SARS-CoV (79.5% homology), while only 50% homology with the Middle East respiratory syndrome coronavirus (MERS) CoV.[@R2]^,^[@R3] The virus, now named SARS-CoV-2, contains a single positive stranded RNA (ribonucleic acid) of 30 kilobases, which encodes for 10 genes.[@R4] Researchers have shown that the virus can enter cells by binding the angiotensin-converting enzyme 2 (ACE2), through its receptor binding domain in the spike protein.[@R5]

The virus causes the coronavirus disease 2019 (COVID-19), with common symptoms such as fever, cough, shortness of breath and fatigue.[@R6]^,^[@R7] Early data indicated that about 20% of patients develop severe COVID-19 requiring hospitalization, including 5% who are admitted to the intensive care unit.[@R8] Initial estimates of the case fatality rates were from 3.4% to 6.6% which is lower than that of SARS or MERS, 9.6% and 34.3% respectively.[@R9]^--^[@R11] The mortality from COVID-19 is higher in people older than 65 years and in people with underlying comorbidities, such as chronic lung disease, serious heart conditions, high blood pressure, obesity and diabetes.[@R12]^--^[@R14]

Community transmission of the virus, as well as anti-viral treatments, can engender novel mutations in the virus, potentially resulting in more virulent strains with higher mortality rates or emergence of strains resistant to treatment.[@R15] Therefore, systematic tracking of demographic and clinical patient information, as well as strain information is indispensable to effectively combat COVID-19.

Here we analysed the SARS-CoV-2 genome from 10 022 samples to understand the variability in the viral genome landscape and to identify emerging clades.

Methods
=======

In total, we downloaded 15 755 genome sequences from the following databases: the Chinese National Microbiology Data Center on 1 February 2020; the Chinese National Genomics Data Center Genome Warehouse on 4 February 2020; GISAID[@R16] on 1 May 2020 and GenBank on 1 May 2020. We removed redundant sequences with the China National Center for Bioinformation annotations. To reduce the number of false positive variants, we removed sequences with more than 50 ambiguous bases.

For this study, we used the sequence of established SARS-CoV-2 reference genome, NC_045512.[@R17] This genome was sequenced in December 2019. Each sample was first aligned to the reference genome in a pairwise manner using EMBOSS needle (Hinxton, Cambridge, England), with a default gap penalty of 10 and extension penalty of 0.5.[@R18] Then, we developed a custom script in Python (Python Software Foundation, Wilmington, United States of America) to extract the differences between the genome variants and the reference genome. Nucleotide variants in the coding regions were converted to corresponding encoded amino acid residues. For the open reading frame 1 (ORF1), we used the protein coordinates from YP_009724389.1[@R19] for translation. Finally, we carefully investigated stop-gained and frameshift variants causing deletions and insertions to detect potential artefacts caused by undetermined or ambiguous bases. The results are provided in a list of variants (available in the data repository).[@R20]

Using the identified recurrent variants, we performed hierarchical clustering in SciPy library, Python, to identify clades. First, a binary matrix of samples and distinct variants was created. Then, we did hierarchical clustering using the Ward's method[@R21] in SciPy library.[@R22]

We investigated the mutation patterns of SARS-CoV-2 to find potential causes of mutations, by looking at the changes in bases. Since coronavirus genomes are positive sense, single stranded RNA, we did not combine C \> T with G \> A mutations.

The spike protein is a key protein for SARS-CoV-2 viral entry and a target for vaccine development. We, therefore, wanted to find amino acid conservation between other coronavirus sequences in the spike protein. We used the basic local alignment search tool BLAST (National Center for Biotechnology Information \[NCBI\], Bethesda, United States)[@R23] followed by the constraint-based multiple alignment tool COBALT (NCBI, Bethesda, United States).[@R24] We carefully investigated mutations within the receptor binding domain and predicted B-cell epitopes.[@R25]^,^[@R26] The mutations were further analysed to identify cross species conservation and to understand the nature of amino acid changes. We visualized the aligned sequence using the open source software alv.[@R27]

For the phylogenetic analysis, we used the open source software Bayesian evolutionary analysis by sampling trees (BEAST), version 2.5.[@R28] BEAST uses a Bayesian Monte-Carlo algorithm generating a distribution of likely phylogenies given a set of priors, based on the probabilities of those tree configurations determined from the viral genomes. This analysis presents a different view than the variant analysis described above and is an independent test of the structure that individual haplogroup markers identify. First, we aligned sequences to NC_045512, using the multiple sequence alignment software, MAFFT.[@R29] Subsequently, we adjusted for length and sequencing errors, by truncating the bases in the 5'-UTR and 3'-UTR, without losing key sites. We excluded sequences showing a variability higher than 30 bases. For an optimal output of the phylogenetic tree, we randomly selected a subset of 2000 samples by using a random number generator in Python. We ran BEAST using sample collection dates with the Hasegawa-Kishino-Yano mutation model,[@R30] with the strict clock mode. Finally, we estimated the mutation rate and median tree height from the resulting BEAST trees.

Results
=======

In total, we analysed 10 022 SARS CoV-2 genomes (sequences are available from the data repository)[@R20] from 68 countries. Most genomes came from the United States of America (3543 samples), followed by the United Kingdom of Great Britain and Northern Ireland (1987 samples) and Australia (760 samples; [Box 1](#B1){ref-type="boxed-text"}). We detected in total 65776 variants with 5775 distinct variants. The 5775 distinct variants consist of 2969 missense mutations, 1965 synonymous mutations, 484 mutations in the non-coding regions, 142 non-coding deletions, 100 in-frame deletions, 66 non-coding insertions, 36 stop-gained variants, 11 frameshift deletions and two in-frame insertions ([Table 1](#T1){ref-type="table"}).

###### Number of samples of severe acute respiratory syndrome coronavirus 2 from each country or territory included in sequence analysis, 2019--2020

United States 3543 samples; United Kingdom 1987 samples; Australia 760 samples; Iceland 461 samples; Netherlands 402 samples; China 342 samples; Belgium 335 samples; Denmark 260 samples; France 218 samples; Spain 148 samples; Russian Federation 141 samples; Canada 117 samples; Luxembourg 112 samples; Sweden 107 samples; Portugal 96 samples; Japan 95 samples; Taiwan, China 85 samples; Singapore 71 samples; Germany 61 samples; Switzerland 55 samples; India 51 samples; Italy 44 samples; Brazil 43 samples; China, Hong Kong Special Administrative Region 43 samples; Greece 41 samples; Republic of Korea 36 samples; Czechia 34 samples; Turkey 25 samples; Argentina 24 samples; Finland 24 samples; Thailand 22 samples; Jordan 20 samples; Norway 18 samples; Austria 15 samples; Senegal 15 samples; Democratic Republic of the Congo 14 samples; Georgia 12 samples; Malaysia 12 samples; Mexico 11 samples; Ireland 10 samples; Latvia 10 samples; Viet Nam 10 samples; Poland 9 samples; Sri Lanka 8 samples; Chile 7 samples; Kuwait 7 samples; New Zealand 6 samples; Costa Rica 5 samples; South Africa 5 samples; Estonia 4 samples; Slovakia 4 samples; Slovenia 4 samples; Algeria 3 samples; Gambia 3 samples; Hungary 3 samples; Israel 3 samples; Pakistan 3 samples; Saudi Arabia 3 samples; Belarus 2 samples; Nepal 2 samples; Peru 2 samples; Philippines 2 samples; Qatar 2 samples; Cambodia 1 sample; Colombia 1 sample; Egypt 1 sample; Iran (Islamic Republic of) 1 sample; and Lithuania 1 sample.

###### Number of gene variants in SARS-CoV-2 genomes,2019--2020

  Genome segment^a^   Missense mutation   Synonymous mutation      Non-coding region             In-frame      Frameshift deletion   Stop-gained   Total                     
  ------------------- ------------------- --------------------- -- ------------------- --------- ---------- -- --------------------- ------------- ------- -------- -------- ----------
  *ORF1ab*            1905                1344                     0                   0         0             57                    2                     7        13       3328
  *S*                 394                 260                      0                   0         0             27                    0                     0        6        687
  *ORF3a*             169                 71                       0                   0         0             5                     0                     1        1        247
  *E*                 27                  15                       0                   0         0             1                     0                     0        0        43
  *M*                 53                  71                       0                   0         0             0                     0                     0        0        124
  *ORF6*              28                  11                       0                   0         0             2                     0                     0        2        43
  *ORF7*              59                  29                       0                   0         0             1                     0                     2        6        97
  *ORF8*              68                  26                       0                   0         0             1                     0                     0        7        102
  *ORF10*             20                  12                       0                   0         0             0                     0                     1        1        34
  *N*                 246                 126                      0                   0         0             6                     0                     0        0        378
  Intergenic          0                   0                        0                   7         2             0                     0                     0        0        9
  5'-UTR              0                   0                        260                 50        37            0                     0                     0        0        347
  3'-UTR              0                   0                        224                 85        27            0                     0                     0        0        336
  **Total**           **2969**            **1965**                 **484**             **142**   **66**        **100**               **2**                 **11**   **36**   **5775**

E: envelope protein; M: membrane glycoprotein; N: nucleocapsid phosphoprotein; ORF: open reading frame; S: spike glycoprotein; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; UTR: untranslated region.

^a^ Genes are in italics.

Note: We compared 10 022 genomes to the NC_045512 genome sequence.[@R17]

Of the 2969 missense variants, 1905 variants are found in ORF1ab, which is the longest ORF occupying two thirds of the entire genome. ORF1ab is transcribed into a multiprotein and subsequently cleaved into 16 nonstructural proteins (NSPs). Of these proteins, NSP3 has the largest number of missense variants among ORF1ab proteins. Of the NSP3 missense variants, A58T was the most common (159 samples) followed by P153L (101 samples; [Table 2](#T2){ref-type="table"}). We also detected mutations in the nonstructural protein RNA-dependent RNA polymerase (RdRp), such as P323L (6319 samples). Deletions are also common in 3′-5′exonuclease (11 deletions) including those resulting in frameshifts. A comprehensive list of variants is available in data repository.[@R20]

###### Number of variants in the open reading frame 1ab of SARS-CoV-2 genomes, by final cleaved protein, 2019--2020

  Final protein^a^   Missense mutation   Synonymous mutation      Non-coding region           In-frame      Frameshift deletion   Stop-gained   Total                    
  ------------------ ------------------- --------------------- -- ------------------- ------- ---------- -- --------------------- ------------- ------- ------- -------- ----------
  NSP1               64                  45                       0                   0       0             13                    0                     1       0        123
  NSP2               237                 130                      0                   0       0             5                     0                     0       0        372
  NSP3               547                 349                      0                   0       0             16                    0                     2       3        917
  NSP4               116                 113                      0                   0       0             1                     0                     0       1        232
  3CLPro             67                  54                       0                   0       0             0                     0                     0       0        121
  NSP6               82                  67                       0                   0       0             4                     1                     2       0        156
  NSP7               27                  21                       0                   0       0             0                     0                     0       0        48
  NSP8               60                  25                       0                   0       0             1                     0                     0       1        87
  NSP9               29                  22                       0                   0       0             0                     0                     0       1        52
  NSP10              25                  25                       0                   0       0             0                     0                     0       2        52
  RdRp               194                 157                      0                   0       0             2                     0                     1       3        357
  Helicase           148                 101                      0                   0       0             0                     0                     0       0        249
  ExoN               141                 118                      0                   0       0             11                    0                     1       2        273
  endoRNase          92                  67                       0                   0       0             3                     0                     0       0        162
  OMT                76                  50                       0                   0       0             1                     1                     0       0        128
  **Total**          **1905**            **1344**                 **0**               **0**   **0**         **57**                **2**                 **7**   **13**   **3329**

3CLPro: 3C like protease; ExoN: 3-'5′ exonuclease; NSP: non-structural protein; OMT: O-methyltransferase; RdRp: RNA-dependent RNA polymerase; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

^a^ The *open reading frame 1ab* gene codes for a polyprotein, which a viral protease cleaves in to several protein after translation.

Note: We compared 10 022 genomes to the NC_045512 genome sequence.[@R17]

Variants with recurrence over 100 samples are shown in [Table 3](#T3){ref-type="table"}. The most common variants were the synonymous variant 3037C \> T (6334 samples), ORF1ab P4715L (RdRp P323L; 6319 samples) and SD614G (6294 samples). They occur simultaneously in over 3000 samples, mainly from Europe and the United States. Other variants including ORF3a Q57H (2893 samples), ORF1ab T265I (NSP3 T85I; 2442 samples), ORF8 L84S (1669 samples), N203_204delinsKR (1573 samples), ORF1ab L3606F (NSP6 L37F; 1070 samples) were the key variants for identifying clades.

###### Variants of SARS-CoV-2 genomes observed in more than 100 samples, 2019--2020

  Genomic change             Type of mutation      Gene/protein         Amino acid change   No. of samples
  -------------------------- --------------------- -------------------- ------------------- ----------------
  **3037C \> T**             Synonymous            *ORF1ab/*NSP3        F924F/F106F         6334
  **14408C \> T**            Missense              *ORF1ab/*RdRp        P4715L/P323L        6319
  **23403A \> G**            Missense              *S*                  D614G               6294
  **241C \> T**              Non-coding            *5'-UTR*             NA                  5928
  **25563G \> T**            Missense              *ORF3a*              Q57H                2893
  **1059C \> T**             Missense              *ORF1ab*/NSP2        T265I/T85I          2442
  **28144T \> C**            Missense              *ORF8*               L84S                1669
  **8782C \> T**             Synonymous            *ORF1ab*/NSP4        S2839S/S76S         1598
  **28881_28883delinsAAC**   Missense              *N*                  203_204delinsKR     1573
  **18060C \> T**            Synonymous            *ORF1ab*/ExoN        L5932L/L7L          1178
  **17858A \> G**            Missense              *ORF1ab*/helicase    Y5865C/Y541C        1166
  **17747C \> T**            Missense              *ORF1ab*/helicase    P5828L/P504L        1147
  **11083G \> T**            Missense              *ORF1ab*/NSP6        L3606F/L37F         1070
  **14805C \> T**            Synonymous            *ORF1ab*/RdRp        Y4847Y/Y455Y        844
  **26144G \> T**            Missense              *ORF3a*              G251V               769
  **20268A \> G**            Synonymous            *ORF1ab*/endoRNase   L6668L/L216L        452
  **17247T \> C**            Synonymous            *ORF1ab*/helicase    R5661R/R337R        325
  **2558C \> T**             Missense              *ORF1ab*/NSP2        P765S/P585S         274
  **15324C \> T**            Synonymous            *ORF1ab*/RdRp        N5020N/N628N        267
  **1605_1607del**           In-frame deletion     *ORF1ab*/NSP2        D448del/D268del     250
  **18877C \> T**            Synonymous            *ORF1ab*/ExoN        L6205L/L280L        234
  **2480A \> G**             Missense              *ORF1ab*/NSP2        I739V/I559V         232
  **27046C \> T**            Missense              *M*                  T175M               221
  **11916C \> T**            Missense              *ORF1ab*/NSP7        S3884L/S25L         185
  **2416C \> T**             Synonymous            *ORF1ab*/NSP2        Y717Y/Y537Y         170
  **1440G \> A**             Missense              *ORF1ab*/NSP2        G392D/G212D         164
  **27964C \> T**            Missense              *ORF8*               S24L                164
  **36C \> T**               Non-coding            *5'-UTR*             NA                  163
  **2891G \> A**             Missense              *ORF1ab*/NSP3        A876T/A58T          159
  **28854C \> T**            Missense              *N*                  S194L               155
  **1397G \> A**             Missense              *ORF1ab*/NSP2        V378I/V198I         139
  **28657C \> T**            Synonymous            *N*                  D128D               139
  **28688T \> C**            Synonymous            *N*                  L139L               138
  **18998C \> T**            Missense              *ORF1ab*/ExoN        A6245V/A320V        137
  **28311C \> T**            Missense              *N*                  P13L                136
  **28863C \> T**            Missense              *N*                  S197L               136
  **9477T \> A**             Missense              *ORF1ab*/NSP4        F3071Y/F308Y        136
  **25979G \> T**            Missense              *ORF3a*              G196V               132
  **29742G \> T**            Non-coding            *3'-UTR*             NA                  131
  **25429G \> T**            Missense              *ORF3a*              V13L                128
  **24034C \> T**            Synonymous            *S*                  N824N               118
  **29870C \> A**            Non-coding            *3'-UTR*             NA                  115
  **28077G \> C**            Missense              *ORF8*               V62L                113
  **26729T \> C**            Synonymous            *M*                  A69A                106
  **27_37del**               Non-coding deletion   *5'-UTR*             NA                  106
  **19_24del**               Non-coding deletion   *5'-UTR*             NA                  105
  **514T \> C**              Synonymous            *ORF1ab*/NSP1        H83H/H83H           105
  **23731C \> T**            Synonymous            *S*                  T723T               102
  **3177C \> T**             Missense              *ORF1ab*/NSP3        P971L/T1198K        101

del: deletion; delins: deletion--insertion; ExoN: 3'-5′ exonuclease; NSP: non-structural protein; M: membrane glycoprotein; N: nucleocapsid phosphoprotein; NA: not applicable; ORF: open reading frame; RdRp: RNA-dependent RNA polymerase; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; S: spike glycoprotein; UTR: untranslated region.

Note: We compared 10 022 genomes to the NC_045512 genome sequence.[@R17]

We identified six major clades with 14 subclades ([Fig. 1](#F1){ref-type="fig"} and [Table 4](#T4){ref-type="table"}). The largest clade is D614G clade with five subclades. Most samples in the D614G clade also display the non-coding variant 241C \> T, the synonymous variant 3037C \> T and ORF1ab P4715L. Within D614G clade, D614G/Q57H/T265I subclade forms the largest subclade with 2391 samples. The second largest major clade is L84S clade, which was observed among travellers from Wuhan in the early days of the outbreak, and the clade consists of 1662 samples with 2 subclades. The L84S/P5828L/ subclade is predominantly observed in the United States. Among the L3606F subclades, L3606F/G251V/ forms the largest group with 419 samples. G251V frequently appears in samples from the United Kingdom (329 samples), Australia (95 samples), the United States (80 samples) and Iceland (76 samples). However, the basal clade now accounts only for a small fraction of genomes (670 samples mainly from China). The remaining two clades D448del and G392D are small and they are without any significant subclades at this point.

![A graphical representation of variants found in SARS-CoV-2 genomes, 2019--2020](BLT.20.253591-F1){#F1}

###### Major clades of SARS-CoV-2 genomes, 2019--2020

  Clade/sublevel 1/sublevel 2       First observation of strain   No. of samples                                             
  --------------------------------- ----------------------------- ----------------------------------- ---------------------- ------
  **Basal^a^**                      Dec 2019                      MN90894                             China                  670
  **D614G//**                       24 Jan 2020                   EPI_ISL_422425                      China                  1889
  D614G/Q57H/                       26 Feb 2020                   EPI_ISL_418219                      France                 469
      D614G/Q57H/T265I              21 Feb 2020                   EPI_ISL_418218                      France                 2391
  D614G/203_204delinsKR/            25 Feb 2020                   EPI_ISL_412912                      Germany                1330
      D614G/203_204delinsKR/T175M   1 Mar 2020                    EPI_ISL_413647 and EPI_ISL_417688   Portugal and Iceland   215
  **L84S//**                        30 Dec 2019                   MT291826                            China                  525
  L84S/P5828L                       20 Feb 2020                   EPI_ISL_413456                      United States          1137
  **L3606F//**                      18 Jan 2020                   EPI_ISL_408481                      China                  182
  L3606F/V378I/                     18 Jan 2020                   EPI_ISL_412981                      China                  127
  L3606F/G251V/                     29 Jan 2020                   EPI_ISL_412974                      Italy                  419
      L3606F/G251V/P765S            20 Feb 2020                   EPI_ISL_415128                      Brazil                 260
  **D448del//**                     8 Feb 2020                    EPI_ISL_410486,                     France                 248
  **G392D//**                       25 Feb 2020                   EPI_ISL_414497                      Germany                160

Del: deletion; delins: deletion--insertion; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

^a^ The reference genome (NC_045512)[@R17] used in this study belongs to the basal clade.

All non-coding deletions are either located within 3'-UTR, 5'-UTR or intergenic regions. Of the in-frame deletions, ORF1 D448del stands out with 250 samples. In contrast, we only detected two distinct in-frame insertions in our data set. We also detected 11 frameshift deletions and 36 stop-gained variants. The recurrent stop-gained variant Y4379\* (NSP10 Y126\*) is found in 51 samples in the D614G clade. NSP10 Y126\* is located only 13 residues upstream of the stop codon; therefore, a truncation may not significantly affect function of the protein. Most of frameshift variants in ORF1ab do not recur except for S135fs (three samples) and L3606fs (two samples). Although frameshift variants are considered deleterious, for instance, S135fs (more precisely S135Rfs\*9) caused by 670_671del, ORF1ab is truncated at residue 143 before NSP2 and translation might resume from the methionine at residue 174 near the end of NSP1. Other notable recurrent frameshift variants include ORF3a V256fs and ORF7 I103fs.

The most common base change is C \> T ([Fig. 2](#F2){ref-type="fig"}). As expected,[@R31] we observed a strong bias in transition versus transversion ratio (7:3). C \> T transitions might be intervened by cytosine deaminases. Surprisingly, G \> T transversions, likely introduced by oxo-guanine from reactive oxygen species,[@R32] were also frequently observed.

![Base pair changes observed in SARS-CoV-2 genomes, 2019--2020](BLT.20.253591-F2){#F2}

Assessing variants in the spike protein revealed 427 distinct non-synonymous variants with many variants located within the receptor binding domain and B-cell epitopes ([Fig. 3](#F3){ref-type="fig"}). Among the variants in the receptor binding domain, V483A (26 samples), G476S (9 samples) and V367F (12 samples) are highly recurrent.

![Annotation of SARS-CO-2 variants in the alignment of the amino acid sequence of the spike protein from several coronaviruses, 2019--2020](BLT.20.253591-F3){#F3}

[Fig. 4](#F4){ref-type="fig"} shows the consensus tree from the phylogenetic analysis. The tree has a coalescence centre with exponential expansion identified by haplotype markers. The colour mapped phylogenies largely support the 14 identified subclades. We note that substantial numbers of samples from the United States show affinity with European lineages rather than those directly derived from East Asia. Except for the earliest cases, European clades dominate even in samples from western states in the United States. Further, European samples tend to associate with lineages that expanded through Australia.

![Phylogenetic tree for the SARS-CoV-2 genomes, 2019--2020](BLT.20.253591-F4){#F4}

Estimation of mutation rate showed a median of 1.12 × 10^−3^ mutations per site-year (95% confidence interval, CI: 9.86 × 10^−4^ to 1.85 × 10^−4^). The median tree height was 5.1 months (95% CI: 4.8 to 5.52).

Discussion
==========

Here we show the evolution of the SARS-Co-2 genome as it has spread across the world. Although, our methods do not allow us to investigate whether the mutations observed led to a loss or gain of function, we can speculate on the implications of viral function of these mutations.

The most common clade identified was the D614G variant, which is located in a B-cell epitope with a highly immunodominant region and may therefore affect vaccine effectiveness.[@R33] Although amino acids are quite conserved in this epitope, we identified 14 other variants besides D614G. Almost all strains with D614G mutation also have a mutation in the protein responsible for replication (ORF1ab P4715L; RdRp P323L), which might affect replication speed of the virus. This protein is the target of the anti-viral drugs, remdesivir and favipiravir, and the susceptibility for mutations suggests that treatment resistive strains may emerge quickly. Mutations in the receptor binding domain of the spike protein suggest that these variants are unlikely to reduce binding affinity with ACE2, since that would decrease the fitness of the virus. V483A and G476S are primarily observed in samples from the United States, whereas V367F is found in samples from China, Hong Kong Special Administrative Region, France and the Netherlands. The V367F and D364Y variants have been reported to enhance the structural stability of the spike protein facilitating more efficient binding to the ACE2 receptor.[@R34] In summary, structural and functional changes concomitant with spike protein mutations should be meticulously studied during therapy design and development.

We detected several non-recurring frameshift variants, which can be sequencing artefacts. The frameshift at Y3 in ORF10, although only detected in one sample, might not be essential for survival of the new coronavirus, since ORF10, a short 38-residue peptide, is not homologous with other proteins in the NCBI repository.

The phylogenetic analysis suggest population structuring in the evolution of SARS-CoV-2. The analysis provides an independent test of the major clades we identified, as well as the geographic expansions of the variants. While the earliest samples from the United Stated appear to be derived from China, belonging either to basal or L84S clades, the European clades, such as D614G/Q57H, tend to associate with most of the subsequent increase in infected people in the United States. D614G was first observed in late January in China and became the largest clade in three months. The mutation rate of 1.12 × 10^−3^ mutations per site-year is similar to 0.80 × 10^−3^ to 2.38 × 10^−3^ mutations per site-year reported for SARS-CoV-1.[@R35]

The rapid increase of infected people will provide more genome samples that could offer further insights to the viral dissemination, particularly the possibility of at least two zoonotic transmissions of SARS-CoV-2 into the human population. An understanding of the biological reservoirs carrying coronaviruses and the modalities of contact with human population through trade, travel or recreation will be important to understand future risks for novel infections. Further, populations may be infected or even re-infected via multiple travel routes.

The number of people with confirmed COVID-19 has rapidly increased over the last five months with no sign of decline in the near future. The fight against COVID-19 will be long, until vaccines and other effective therapies are developed. To facilitate rapid therapeutic development, clinicopathological, genomic and other societal information must be shared with researchers, physicians and public health officials. Given the evolving nature of the SARS-CoV-2 genome, drug and vaccine developers should continue to be vigilant for emergence of new variants or sub-strains of the virus.
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